ArticleFrontiers in pharmacology2026
Association of postoperative modified Yaotong Tang with early recovery after unilateral biportal endoscopy for lumbar disc herniation: a retrospective comparative cohort study using propensity score weighting.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Modified Yaotong Tang (MYT) is used as an adjunctive postoperative herbal decoction in traditional Chinese medicine practice for lumbar disorders, but its association with early recovery after unilateral biportal endoscopy (UBE) and the reproducibility of its clinical preparation remain insufficiently characterized. Methods: This single-center retrospective comparative cohort study screened 235 patients with symptomatic single-level lumbar disc herniation (LDH) who underwent surgical treatment between September 2022 and September 2025. Of these, 182 met the eligibility criteria, including 122 patients in the primary UBE analytic cohort (62 UBE + MYT and 60 UBE alone) and 60 patients in a transforaminal lumbar interbody fusion cohort retained only as a descriptive external benchmark. The primary UBE comparison was adjusted using inverse probability of treatment weighting (IPTW). Results: Compared with UBE alone, the UBE + MYT cohort showed lower IPTW-adjusted Visual Analog Scale scores at postoperative day (POD) 3 (3.88 vs. 4.67; mean difference, -0.79; 95% CI, -1.06 to -0.53; P < 0.001) and POD7 (2.85 vs. 3.73; mean difference, -0.88; 95% CI, -1.14 to -0.62; P < 0.001). IPTW-adjusted IL-6 and CRP levels were lower during the first postoperative week, and follow-up Japanese Orthopaedic Association scores were higher in the UBE + MYT cohort. MYT administration was verified using de-identified medical, pharmacy/decoction-room, nursing, and follow-up records. No Clavien-Dindo grade III or higher adverse events were observed. Discussion: Postoperative MYT use was associated with lower early postoperative pain scores, lower inflammatory biomarker levels, and better subsequent functional recovery after UBE for LDH. No severe safety signal was observed, but causality and rare herb-related safety events require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.